A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A phase 1/2 trial of GNC-038 in non-Hodgkin lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05623982 by Sichuan Baili Pharmaceutical Co., Ltd., with 40 participants planned, started 2022-09-26 and due to reach its primary completion in 2026-12. Interventions recorded: GNC-038.
Similar pages
not linked directly; found by shared links- TrialA Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Shares SystImmune / Sichuan Biokin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Shares SystImmune / Sichuan Biokin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.